Conference Coverage

VIDEO: 'Target: Stroke' program hopes to add hospitals, increase timely treatment


 

SAN DIEGO – The average proportion of ischemic patients who got tissue plasminogen activator within an hour of arriving at participating hospitals increased from 30% before initiation of the Target: Stroke project to 53% afterward. We interviewed Dr. Gregg C. Fonarow about the new phase II of Target: Stroke, launched at the International Stroke Conference , which aims for timely door-to-needle treatment in 75% of stroke patients.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel .

Recommended Reading

Video: Positive trends for outcomes in uric acid stroke trial gives optimism
MDedge Internal Medicine
Video: Study hints uric acid reduces acute stroke symptoms
MDedge Internal Medicine
Uric acid for stroke trials to continue
MDedge Internal Medicine
VIDEO: Postpartum elevated thrombosis risk lasts 12 weeks
MDedge Internal Medicine
Postpartum thrombosis risk high for 12 weeks
MDedge Internal Medicine
VIDEO: Longer period of postpartum thromboembolic risk raises therapeutic questions
MDedge Internal Medicine
VIDEO: Moderate exercise reduced women’s stroke risk
MDedge Internal Medicine
Moderate exercise reduces female stroke risk
MDedge Internal Medicine
VIDEO: Highlights of the Annual Stroke Conference
MDedge Internal Medicine
'Target: Stroke' program gets most patients timely treatment
MDedge Internal Medicine

Related Articles